Abbott Abbokinase
Additional manufacturing deficiencies found during inspections of Abbott and the company's supplier of human kidney cells, BioWittaker, FDA said in a July 16 "Talk Paper." FDA has sent a letter to Abbott identifying "numerous significant deviations from current good manufacturing practices." Abbott may not distribute Abbokinase (urokinase) until the company completes investigations of reovirus and mycoplasm contamination, including the source of human kidney cells and validates manufacturing processes. The agency conducted the inspections after a January letter to health care professionals alerting physicians of the risk of transmitting infectious agents (1"The Pink Sheet" March 22, In Brief)
More from Archive
More from Pink Sheet
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.